Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 618-522-8 | CAS number: 9030-09-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 27 February 1995 to 14 June 1995
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 995
- Report date:
- 1995
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Active enzyme protein of Cyclomaltodextrin glucanotransferase (EC no. 618-522-8, CAS no.9030-09-5, EC name Cyclomaltodextrin glucanotransferase , Enzyme class no 2.4.1.19 )
- Molecular formula:
- n.a.
- IUPAC Name:
- Active enzyme protein of Cyclomaltodextrin glucanotransferase (EC no. 618-522-8, CAS no.9030-09-5, EC name Cyclomaltodextrin glucanotransferase , Enzyme class no 2.4.1.19 )
- Reference substance name:
- Protein as a constituent of enzyme deriving from the fermentation or extraction process
- Molecular formula:
- Not available. See remarks.
- IUPAC Name:
- Protein as a constituent of enzyme deriving from the fermentation or extraction process
- Reference substance name:
- Inorganic salts as a constituent of enzyme deriving from the fermentation or extraction process
- Molecular formula:
- Not available. See remarks.
- IUPAC Name:
- Inorganic salts as a constituent of enzyme deriving from the fermentation or extraction process
- Reference substance name:
- Carbohydrates constituent of enzyme deriving from the fermentation or extraction process.
- Molecular formula:
- Not available. See remarks.
- IUPAC Name:
- Carbohydrates constituent of enzyme deriving from the fermentation or extraction process.
- Reference substance name:
- Lipids as a constituent of enzyme deriving from the fermentation or extraction process
- Molecular formula:
- Not available. See remarks.
- IUPAC Name:
- Lipids as a constituent of enzyme deriving from the fermentation or extraction process
- Test material form:
- liquid
- Details on test material:
- - Lot/batch No.: PPA 4357
- Expiration date of the lot/batch: No specific expiry date. At least 10 years or as long as enzyme activity is preserved.
- Stability under test conditions: Solutions in water are stable for at least 24 hours at room temperature or 4 degrees Celsius.
- Storage condition of test material: Refrigerated in the dark.
Constituent 1
Constituent 2
Constituent 3
Constituent 4
Constituent 5
Test animals
- Species:
- rat
- Strain:
- other: CD strain
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Limited
- Females nulliparous and non-pregnant: Yes
- Age at study initiation: 33-40 days
- Weight at study initiation: Weighed 91 to 123 g seven days after arrival.
- Fasting period before study: None
- Housing: The cages used were Type TRIS made of a stainless steel body measuring 54 x 38 x 20 cm with a stainless steel mesh lid and floor.
- Diet: Ad libitum pelleted rodent diet, RMI(E) SQC.
- Water: Ad libitum. Water, taken from the public supply (Suffolk Water Company, Lowestoft, England}, was freely available via polycarbonate bottles fitted with sipper tubes.
- Acclimation period: 12 days
ENVIRONMENTAL CONDITIONS
- Temperature : 21°C
- Humidity : 55% RH
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 21.07.94 To: 17.10.94
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Remarks:
- and purified water for the other control
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test enzyme was supplied in a 24% aqueous solution of monopropylene glycol. It was administered to high dosage animals as received at a volume-dosage of 10 mL/kg bodyweight. For the lower dosages, the test enzyme was diluted with an appropriate amount of purified water (obtained by reverse osmosis) to provide the required dosages at a constant volume-dosage. Vehicle control animals (Group 2) received a 24% aqueous solution of monopropylene glycol in purified water whilst the other control group (Group 1) received purified water only. The volume dosage in each case was 10 mL/kg bodyweight. All formulations were prepared on the day before administration.
VEHICLE
- Concentration in vehicle: 24% aqueous solution of monopropylene glycol.
- Amount of vehicle (if gavage): constant volume 10 mL/kg body weight. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples of formulations prepared for administration on one occasion in Week 1 and 13 were taken for content check analysis . All samples were deep frozen and despatched for analysis. The results of these analyses indicated values approximately 30-65% higher than expected; these were considered to be acceptable as the method for determining the enzyme activity was changed after the initial determination.
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- Daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Remarks:
- Concentration is in mg TOS
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- Remarks:
- Concentration is in mg TOS
- Dose / conc.:
- 2 600 mg/kg bw/day (nominal)
- Remarks:
- Concentration is in mg TOS
- No. of animals per sex per dose:
- 20
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The highest dose (100%) is the maximum practical dose and represents administration of the enzyme, as received, at a volume dosage of 10 mL/kg body weight.
- Positive control:
- Not included
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: At least twice daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Individual observations of all animals were also recorded before and after dosing on each day of treatment as indicated below. The timing of these observations were performed to establish and confirm any pattern of signs. The schedule was: Week 1 daily; Weeks 2-4 twice weekly (middle and end of each week); Weeks 5-13 once each week.
BODY WEIGHT: Yes
- Time schedule for examinations: The weight of each animal was recorded during the acclimatisation period, on the day that treatment commenced, at weekly intervals throughout the treatment period and before necropsy.
FOOD CONSUMPTION: Yes
- The weight of food supplied to each cage, that remaining and an estimate of the amount spilled was recorded for each week throughout the treatment period. From these records the mean weekly consumption per animal was calculated for each cage.
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: Not stated.
- Dose groups that were examined: Observations were bilateral unless otherwise indicated.
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Week 13
Differential leucocyte counts were determined automatically by counting the numbers of lymphocytes, neutrophils, monocytes, eosinophils, basophils and large unstained cells in the instrument sample.
CLINICAL CHEMISTRY: Yes
The concentration of each protein fraction was determined by reference to the percentage value and to the total protein concentration. Albumin to globulin (A/G) ratios were calculated from the percentage values before conversion to absolute concentrations. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Other examinations:
- ORGAN WEIGHTS: Yes.
The weights of adrenals, kidneys, testes and thyroid (with parathyroids) were separately recorded for left and right sides and summed for presentation in the tables of group mean values and appendices of individual values. - Statistics:
- The main tests used were analysis of covariance (ANOCOVA), Student's t-test, Fisher's Exact Probability test, Kruskall-Wallace, Mann-Whitney U-test. Significant differences between the groups compared were expressed at the 5% (p<0.05) level.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- Salivation associated with dosing was observed on a few occasions in isolated animals receiving 2.6 g TOS/kg/day. In view of the very few animals affected this could not, with any confidence, be ascribed to treatment.
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One female, a control receiving purified water, died during Week 13. There were no significant signs before death. Necropsy or histopathological examination could not establish a possible cause of death in view of extensive cannibalisation.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- The weight gains of males receiving 0.5 g TOS/kg/day were slightly lower than those of either group of control males but, in the absence of a similar finding among males receiving the highest dosage, this was considered fortuitous.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- The amount of food consumed by males receiving 0.5 g TOS/kg/day was slightly lower than that of the purified water control group but, in the absence of a similiar finding among those receiving the highest dosage, this was considered fortuitous.
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Males receiving 2.6 g TOS/kg/day had slightly low haemoglobin concentrations when compared with both Control groups (p<0.05). Since other erythrocyte characteristics (packed cell volumes, erythrocyte counts and erythrocytic indices) were unaffected and no similar trend was observed in females this could not, with any confidence, be attributed to treatment. Several inter-group differences attained statistical significance when compared with either of the control groups (p<0.05) but these were minor, lacked dosage-relationship or were inconsistent between the sexes and were therefore attributed to normal biological variation.
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- After 13 weeks of treatment, liver weights were slightly high, when compared with the control group, in females that received 2.6 g TOS/kg/day. The liver weights of males were clearly unaffected by treatment. In addition, the kidney weights of females that received 2.6 g TOS/kg/day were also slightly high. However, as the female low dose kidney weights were similarly high, this change was considered to have arisen by chance and not as a consequence of treatment.
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Reactive hyperplasia of lymphocytic tissue in the mandibular lymph nodes appeared to be slightly increased in incidence and severity in the treated males, compared with the control groups, but the finding did not show a clear dose relationship.
Examination of the hearts of control and high dose males suggested that there may have been a treatment-related increased incidence of chronic myocarditis. However, when the examination was extended to the other controls and treated groups, the incidence seen at 2.6 g TOS/kg/day was similar to that in the control group. It was therefore concluded that treatment did not cause any change in the heart. - Histopathological findings: neoplastic:
- no effects observed
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 2 600 mg/kg bw/day (nominal)
- Based on:
- other: total organic solids (TOS)
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects were seen so NOAEL was the highest dose administered.
Target system / organ toxicity
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- It was concluded that the administration of CGT-ase SP 501, batch PPA 4357 at dosages 0.1, 0.5 or 2.6 g TOS/kg/day to CD rats for 13 weeks did not produce any evidence of toxicity.
- Executive summary:
Groups of 20 male and 20 female CD rats received CGT-ase SP 501, batch PPA 4357 at 4, 20 or 100% as supplied (equivalent to 0.1, 0.5 or 2.6 g TOS/kg/day) by daily oral gavage administration for 13 weeks. Two similarly constituted control groups received either purified water or a 24% aqueous solution of monopropylene glycol and each served to generate contemporaneous control data.
There were no treatment-related signs. Weight gains, food intakes and food conversion efficiencies were unaffected by treatment. There were no changes in the blood that were related to treatment. Liver weights were slightly high after 13 weeks in females given 2.6 g TOS/kg/day. The incidence of reactive hyperplasia of the mandibular lymph nodes in males was slightly high when compared with the vehicle controls.
It was concluded that the administration of CGT-ase SP 501, batch PPA 4357 at dosages 0.1, 0.5 or 2.6 g TOS/kg/day to CD rats for 13 weeks did not produce any evidence of toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
